Dimerix (ASX:DXB) is one of the few ASX biotechs in the middle of a Phase 3 trial, and it even has data showing the trial is a success. After years of hard work, the company has advanced its DMX-200 drug into a Phase 3 trial, and it has secured commercial deals worth over A$300m even prior to the trial.
Despite being one of the most successful ASX healthcare stocks this year (having gained over 500%), it is priced less than other Phase 3 biotechs, and could gain even more if it is…
Read More…
Source: https://stocksdownunder.com/article/dimerix-asxdxb-phase-3-biotech/